Piramal Pharma Schedules Board Meeting and Earnings Call for Q4FY26 Results

Piramal Pharma Limited has announced that its Board of Directors will convene on Tuesday, April 28, 2026, to review and approve the company's audited financial results for the fourth quarter and full financial year ended March 31, 2026. Additionally, the pharmaceutical company will host an earnings conference call on April 29, 2026, to discuss these results with investors and analysts.

Board Meeting Details

The upcoming board meeting has been scheduled in compliance with Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will focus on considering and approving both standalone and consolidated audited financial results for Q4FY26.

Meeting Details:	Information
Date:	Tuesday, April 28, 2026
Purpose:	Audited Financial Results (Standalone and Consolidated)
Period Covered:	Quarter and Financial Year ended March 31, 2026
Regulatory Compliance:	SEBI Listing Regulations, Regulation 29

Earnings Conference Call Schedule

Piramal Pharma Limited will host a conference call for investors and analysts on April 29, 2026, from 9:30 AM to 10:15 AM IST to discuss its Q4 and full-year FY2026 results. The call will accommodate participants from multiple time zones with dedicated dial-in numbers.

Conference Call Details:	Information
Date:	April 29, 2026
Time:	9:30 AM to 10:15 AM IST
India Primary:	+91 22 6280 1461 / +91 22 7115 8320
India Toll Free:	1 800 120 1221
USA Toll Free:	18667462133
UK Toll Free:	08081011573

Trading Window Closure

In accordance with regulatory requirements, Piramal Pharma Limited has implemented a trading window closure for company securities. The trading window, which initially closed on Wednesday, April 1, 2026, will remain closed until Thursday, April 30, 2026, covering both days inclusive.

Trading Window:	Timeline
Closure Start Date:	April 1, 2026
Closure End Date:	April 30, 2026
Duration:	Both days inclusive
Reason:	Board meeting for financial results

Regulatory Communication

The company has formally notified both BSE Limited and National Stock Exchange of India Limited about the scheduled board meeting and conference call. The communication was signed by Pratibha Mishra, Interim Company Secretary, and digitally submitted on April 17, 2026. This notification ensures compliance with SEBI's listing obligations under Regulation 30 and provides transparency to investors and market participants regarding the upcoming financial results disclosure.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.92%	+4.13%	+7.30%	-23.34%	-32.90%	-19.78%

Piramal Pharma has officially received the Establishment Inspection Report (EIR) from the US FDA for its Lexington manufacturing facility, confirming the Voluntary Action Indicated (VAI) status and marking the successful closure of the regulatory inspection.

Official Regulatory Disclosure

The company submitted a formal disclosure to BSE and NSE under Regulation 30 of SEBI regulations, confirming receipt of the EIR with VAI classification. The intimation was filed as the first working day communication following receipt of the official report from the US FDA.

Parameter:	Details
Facility Location:	Lexington, Kentucky, USA
Inspection Status:	VAI (Voluntary Action Indicated)
Report Type:	Establishment Inspection Report (EIR)
Regulatory Framework:	SEBI Regulation 30 Compliance

Inspection Timeline and Process

The US FDA inspection process began with the initial intimation dated December 11, 2025, when Piramal Pharma first disclosed the ongoing regulatory review at its Lexington facility. The completion of the inspection with EIR receipt represents the culmination of the regulatory assessment process.

VAI Status Implications

The Voluntary Action Indicated classification indicates that while the FDA may have identified certain areas for improvement during the inspection, the overall compliance framework at the Lexington facility meets acceptable regulatory standards. This status allows the facility to continue manufacturing operations while addressing any observations made during the inspection process.

Manufacturing Operations Continuity

With the official closure of the FDA inspection and receipt of the EIR, Piramal Pharma's Lexington facility maintains its operational capabilities. The regulatory clearance supports the company's ongoing pharmaceutical manufacturing activities and ensures continuity in market supply commitments for its product portfolio.